-
1
-
-
84875989422
-
The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications
-
Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Hoyer-Hansen G, Eefsen RL, Reynolds AR, Brodt P. The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res. 2013; 73:2031-2043.
-
(2013)
Cancer Res.
, vol.73
, pp. 2031-2043
-
-
Van den Eynden, G.G.1
Majeed, A.W.2
Illemann, M.3
Vermeulen, P.B.4
Bird, N.C.5
Hoyer-Hansen, G.6
Eefsen, R.L.7
Reynolds, A.R.8
Brodt, P.9
-
2
-
-
76949103841
-
Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents
-
Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clinical breast cancer. 2010; 10:64-73.
-
(2010)
Clinical breast cancer.
, vol.10
, pp. 64-73
-
-
Yardley, D.A.1
-
4
-
-
84880044601
-
Tight junction proteins: from barrier to tumorigenesis
-
Runkle EA, Mu D. Tight junction proteins: from barrier to tumorigenesis. Cancer Lett. 2013; 337:41-48.
-
(2013)
Cancer Lett.
, vol.337
, pp. 41-48
-
-
Runkle, E.A.1
Mu, D.2
-
6
-
-
79955009775
-
The Claudin family and its role in cancer and metastasis
-
Escudero-Esparza A, Jiang WG, Martin TA. The Claudin family and its role in cancer and metastasis. Front Biosci. 2011; 16:1069-1083.
-
(2011)
Front Biosci.
, vol.16
, pp. 1069-1083
-
-
Escudero-Esparza, A.1
Jiang, W.G.2
Martin, T.A.3
-
7
-
-
35349015674
-
Selective upregulation of claudin-1 and claudin-2 in colorectal cancer
-
Kinugasa T, Huo Q, Higashi D, Shibaguchi H, Kuroki M, Tanaka T, Futami K, Yamashita Y, Hachimine K, Maekawa S, Nabeshima K, Iwasaki H. Selective upregulation of claudin-1 and claudin-2 in colorectal cancer. Anticancer Res. 2007; 27:3729-3734.
-
(2007)
Anticancer Res.
, vol.27
, pp. 3729-3734
-
-
Kinugasa, T.1
Huo, Q.2
Higashi, D.3
Shibaguchi, H.4
Kuroki, M.5
Tanaka, T.6
Futami, K.7
Yamashita, Y.8
Hachimine, K.9
Maekawa, S.10
Nabeshima, K.11
Iwasaki, H.12
-
8
-
-
52649123158
-
Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation
-
Weber CR, Nalle SC, Tretiakova M, Rubin DT, Turner JR. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008; 88:1110-1120.
-
(2008)
Lab Invest.
, vol.88
, pp. 1110-1120
-
-
Weber, C.R.1
Nalle, S.C.2
Tretiakova, M.3
Rubin, D.T.4
Turner, J.R.5
-
9
-
-
77249166583
-
Symplekin promotes tumorigenicity by up-regulating claudin-2 expression
-
Buchert M, Papin M, Bonnans C, Darido C, Raye WS, Garambois V, Pelegrin A, Bourgaux JF, Pannequin J, Joubert D, Holle F. Symplekin promotes tumorigenicity by up-regulating claudin-2 expression. Proc Natl Acad Sci U S A. 2010; 107:2628-2633.
-
(2010)
Proc Natl Acad Sci U S A.
, vol.107
, pp. 2628-2633
-
-
Buchert, M.1
Papin, M.2
Bonnans, C.3
Darido, C.4
Raye, W.S.5
Garambois, V.6
Pelegrin, A.7
Bourgaux, J.F.8
Pannequin, J.9
Joubert, D.10
Holle, F.11
-
10
-
-
79960706000
-
Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation
-
Dhawan P, Ahmad R, Chaturvedi R, Smith J, Midha R, Mittal M, Krishnan M, Chen X, Eschrich S, Yeatman T. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene. 2011; 30:3234-3247.
-
(2011)
Oncogene.
, vol.30
, pp. 3234-3247
-
-
Dhawan, P.1
Ahmad, R.2
Chaturvedi, R.3
Smith, J.4
Midha, R.5
Mittal, M.6
Krishnan, M.7
Chen, X.8
Eschrich, S.9
Yeatman, T.10
-
11
-
-
85027947290
-
Claudins and tricellulin in fibrolamellar hepatocellular carcinoma
-
Patonai A, Erdelyi-Belle B, Korompay A, Somoracz A, Straub BK, Schirmacher P, Kovalszky I, Lotz G, Kiss A, Schaff Z. Claudins and tricellulin in fibrolamellar hepatocellular carcinoma. Virchows Archiv : an international journal of pathology. 2011; 458:679-688.
-
(2011)
Virchows Archiv : an international journal of pathology.
, vol.458
, pp. 679-688
-
-
Patonai, A.1
Erdelyi-Belle, B.2
Korompay, A.3
Somoracz, A.4
Straub, B.K.5
Schirmacher, P.6
Kovalszky, I.7
Lotz, G.8
Kiss, A.9
Schaff, Z.10
-
12
-
-
79952382617
-
The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue
-
Jung H, Jun KH, Jung JH, Chin HM, Park WB. The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. The Journal of surgical research. 2011; 167:e185-191.
-
(2011)
The Journal of surgical research.
, vol.167
, pp. e185-191
-
-
Jung, H.1
Jun, K.H.2
Jung, J.H.3
Chin, H.M.4
Park, W.B.5
-
13
-
-
84878954671
-
Distinct claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas
-
Holczbauer A, Gyongyosi B, Lotz G, Szijarto A, Kupcsulik P, Schaff Z, Kiss A. Distinct claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2013; 61:294-305.
-
(2013)
The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society.
, vol.61
, pp. 294-305
-
-
Holczbauer, A.1
Gyongyosi, B.2
Lotz, G.3
Szijarto, A.4
Kupcsulik, P.5
Schaff, Z.6
Kiss, A.7
-
14
-
-
45549095112
-
Downregulation of claudin-2 in breast carcinomas is associated with advanced disease
-
Kim T, Huh J, Lee S, Kang H, Kim G, An H. Downregulation of claudin-2 in breast carcinomas is associated with advanced disease. Histopathology. 2008; 53:48-55.
-
(2008)
Histopathology.
, vol.53
, pp. 48-55
-
-
Kim, T.1
Huh, J.2
Lee, S.3
Kang, H.4
Kim, G.5
An, H.6
-
15
-
-
79951675378
-
Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis
-
Szasz A, Tokes A, Micsinai M, Krenacs T, Jakab C, Lukacs L, Nemeth Z, Baranyai Z, Dede K, Madaras L. Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clinical and Experimental Metastasis. 2011; 28:55-63.
-
(2011)
Clinical and Experimental Metastasis.
, vol.28
, pp. 55-63
-
-
Szasz, A.1
Tokes, A.2
Micsinai, M.3
Krenacs, T.4
Jakab, C.5
Lukacs, L.6
Nemeth, Z.7
Baranyai, Z.8
Dede, K.9
Madaras, L.10
-
16
-
-
84864619220
-
Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes
-
Tabariès S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol. 2012; 32:2979-2991.
-
(2012)
Mol Cell Biol.
, vol.32
, pp. 2979-2991
-
-
Tabariès, S.1
Dupuy, F.2
Dong, Z.3
Monast, A.4
Annis, M.G.5
Spicer, J.6
Ferri, L.E.7
Omeroglu, A.8
Basik, M.9
Amir, E.10
Clemons, M.11
Siegel, P.M.12
-
17
-
-
79952759508
-
Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes
-
Tabariès S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, Russo C, Hassanain M, Metrakos P, Diaz Z, Basik M, Bertos N, Park M, Guettier C, Adam R, Hallett M, et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene. 2011; 30:1318-1328.
-
(2011)
Oncogene.
, vol.30
, pp. 1318-1328
-
-
Tabariès, S.1
Dong, Z.2
Annis, M.G.3
Omeroglu, A.4
Pepin, F.5
Ouellet, V.6
Russo, C.7
Hassanain, M.8
Metrakos, P.9
Diaz, Z.10
Basik, M.11
Bertos, N.12
Park, M.13
Guettier, C.14
Adam, R.15
Hallett, M.16
-
18
-
-
84892986572
-
Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences
-
Kimbung S, Kovacs A, Bendahl PO, Malmstrom P, Ferno M, Hatschek T, Hedenfalk I. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Molecular oncology. 2014; 8:119-128.
-
(2014)
Molecular oncology.
, vol.8
, pp. 119-128
-
-
Kimbung, S.1
Kovacs, A.2
Bendahl, P.O.3
Malmstrom, P.4
Ferno, M.5
Hatschek, T.6
Hedenfalk, I.7
-
19
-
-
79960706000
-
Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation
-
Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK, Krishnan M, Chen X, Eschrich S, Yeatman TJ, Harris RC, Washington MK, Wilson KT, Beauchamp RD, Singh AB. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene. 2011; 30:3234-3247.
-
(2011)
Oncogene.
, vol.30
, pp. 3234-3247
-
-
Dhawan, P.1
Ahmad, R.2
Chaturvedi, R.3
Smith, J.J.4
Midha, R.5
Mittal, M.K.6
Krishnan, M.7
Chen, X.8
Eschrich, S.9
Yeatman, T.J.10
Harris, R.C.11
Washington, M.K.12
Wilson, K.T.13
Beauchamp, R.D.14
Singh, A.B.15
-
20
-
-
7944237784
-
The interplay between Src family kinases and receptor tyrosine kinases
-
Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004; 23:7957-7968.
-
(2004)
Oncogene.
, vol.23
, pp. 7957-7968
-
-
Bromann, P.A.1
Korkaya, H.2
Courtneidge, S.A.3
-
21
-
-
4544235743
-
C-Src and cooperating partners in human cancer
-
Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell. 2004; 6:209-214.
-
(2004)
Cancer Cell.
, vol.6
, pp. 209-214
-
-
Ishizawar, R.1
Parsons, S.J.2
-
22
-
-
48749118203
-
Targeting Src in breast cancer
-
Finn RS. Targeting Src in breast cancer. Ann Oncol. 2008; 19:1379-1386.
-
(2008)
Ann Oncol.
, vol.19
, pp. 1379-1386
-
-
Finn, R.S.1
-
23
-
-
33645072205
-
Treatment for advanced tumors: SRC reclaims center stage
-
Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res. 2006; 12:1398-1401.
-
(2006)
Clin Cancer Res.
, vol.12
, pp. 1398-1401
-
-
Summy, J.M.1
Gallick, G.E.2
-
24
-
-
77950284093
-
LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer
-
Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res. 2010; 70:2296-2306.
-
(2010)
Cancer Res.
, vol.70
, pp. 2296-2306
-
-
Choi, Y.L.1
Bocanegra, M.2
Kwon, M.J.3
Shin, Y.K.4
Nam, S.J.5
Yang, J.H.6
Kao, J.7
Godwin, A.K.8
Pollack, J.R.9
-
25
-
-
78549278133
-
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells
-
Hochgrafe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res. 2010; 70:9391-9401.
-
(2010)
Cancer Res.
, vol.70
, pp. 9391-9401
-
-
Hochgrafe, F.1
Zhang, L.2
O'Toole, S.A.3
Browne, B.C.4
Pinese, M.5
Porta Cubas, A.6
Lehrbach, G.M.7
Croucher, D.R.8
Rickwood, D.9
Boulghourjian, A.10
Shearer, R.11
Nair, R.12
Swarbrick, A.13
Faratian, D.14
Mullen, P.15
Harrison, D.J.16
-
26
-
-
60249090183
-
Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors
-
Laplante Y, Rancourt C, Poirier D. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors. Molecular and cellular endocrinology. 2009; 301:146-153.
-
(2009)
Molecular and cellular endocrinology.
, vol.301
, pp. 146-153
-
-
Laplante, Y.1
Rancourt, C.2
Poirier, D.3
-
27
-
-
33845209913
-
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
-
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10:515-527.
-
(2006)
Cancer Cell.
, vol.10
, pp. 515-527
-
-
Neve, R.M.1
Chin, K.2
Fridlyand, J.3
Yeh, J.4
Baehner, F.L.5
Fevr, T.6
Clark, L.7
Bayani, N.8
Coppe, J.P.9
Tong, F.10
Speed, T.11
Spellman, P.T.12
DeVries, S.13
Lapuk, A.14
Wang, N.J.15
Kuo, W.L.16
-
28
-
-
84860851588
-
Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells
-
Ikari A, Sato T, Watanabe R, Yamazaki Y, Sugatani J. Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells. Biochim Biophys Acta. 2012; 1823:1110-1118.
-
(2012)
Biochim Biophys Acta.
, vol.1823
, pp. 1110-1118
-
-
Ikari, A.1
Sato, T.2
Watanabe, R.3
Yamazaki, Y.4
Sugatani, J.5
-
29
-
-
0141781040
-
Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor
-
Monje P, Marinissen MJ, Gutkind JS. Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol Cell Biol. 2003; 23:7030-7043.
-
(2003)
Mol Cell Biol.
, vol.23
, pp. 7030-7043
-
-
Monje, P.1
Marinissen, M.J.2
Gutkind, J.S.3
-
30
-
-
81255135837
-
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
-
DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011; 17:1514-1520.
-
(2011)
Nat Med.
, vol.17
, pp. 1514-1520
-
-
DeRose, Y.S.1
Wang, G.2
Lin, Y.C.3
Bernard, P.S.4
Buys, S.S.5
Ebbert, M.T.6
Factor, R.7
Matsen, C.8
Milash, B.A.9
Nelson, E.10
Neumayer, L.11
Randall, R.L.12
Stijleman, I.J.13
Welm, B.E.14
Welm, A.L.15
-
31
-
-
77952840150
-
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance
-
Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer. 2010; 116:2665-2672.
-
(2010)
Cancer.
, vol.116
, pp. 2665-2672
-
-
Kantarjian, H.1
le Coutre, P.2
Cortes, J.3
Pinilla-Ibarz, J.4
Nagler, A.5
Hochhaus, A.6
Kimura, S.7
Ottmann, O.8
-
32
-
-
79952743082
-
Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia
-
Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Current opinion in investigational drugs. 2010; 11:1450-1465.
-
(2010)
Current opinion in investigational drugs.
, vol.11
, pp. 1450-1465
-
-
Santos, F.P.1
Kantarjian, H.2
Cortes, J.3
Quintas-Cardama, A.4
-
33
-
-
33846018356
-
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
-
Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood. 2007; 109:306-314.
-
(2007)
Blood.
, vol.109
, pp. 306-314
-
-
Yokota, A.1
Kimura, S.2
Masuda, S.3
Ashihara, E.4
Kuroda, J.5
Sato, K.6
Kamitsuji, Y.7
Kawata, E.8
Deguchi, Y.9
Urasaki, Y.10
Terui, Y.11
Ruthardt, M.12
Ueda, T.13
Hatake, K.14
Inui, K.15
Maekawa, T.16
-
34
-
-
40849135781
-
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines
-
Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, Maekawa T. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leukemia research. 2008; 32:980-983.
-
(2008)
Leukemia research.
, vol.32
, pp. 980-983
-
-
Deguchi, Y.1
Kimura, S.2
Ashihara, E.3
Niwa, T.4
Hodohara, K.5
Fujiyama, Y.6
Maekawa, T.7
-
35
-
-
38449089726
-
C-Jun, a crucial molecule in metastasis of breast cancer and potential target for biotherapy
-
Zhang Y, Pu X, Shi M, Chen L, Qian L, Song Y, Yuan G, Zhang H, Yu M, Hu M, Shen B, Guo N. c-Jun, a crucial molecule in metastasis of breast cancer and potential target for biotherapy. Oncol Rep. 2007; 18:1207-1212.
-
(2007)
Oncol Rep.
, vol.18
, pp. 1207-1212
-
-
Zhang, Y.1
Pu, X.2
Shi, M.3
Chen, L.4
Qian, L.5
Song, Y.6
Yuan, G.7
Zhang, H.8
Yu, M.9
Hu, M.10
Shen, B.11
Guo, N.12
-
36
-
-
84855748821
-
Phase II trial of saracatinib (AZD0530), an oral SRCinhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer
-
Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A, Pellegrino C, Bromberg J, Dang C, Theodoulou M, Massague J, Norton L, Hudis C, Traina TA. Phase II trial of saracatinib (AZD0530), an oral SRCinhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clinical breast cancer. 2011; 11:306-311.
-
(2011)
Clinical breast cancer.
, vol.11
, pp. 306-311
-
-
Gucalp, A.1
Sparano, J.A.2
Caravelli, J.3
Santamauro, J.4
Patil, S.5
Abbruzzi, A.6
Pellegrino, C.7
Bromberg, J.8
Dang, C.9
Theodoulou, M.10
Massague, J.11
Norton, L.12
Hudis, C.13
Traina, T.A.14
-
37
-
-
80455173400
-
Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study
-
Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011; 17:6905-6913.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 6905-6913
-
-
Finn, R.S.1
Bengala, C.2
Ibrahim, N.3
Roche, H.4
Sparano, J.5
Strauss, L.C.6
Fairchild, J.7
Sy, O.8
Goldstein, L.J.9
-
38
-
-
80455132309
-
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer
-
Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res. 2011; 17:6897-6904.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 6897-6904
-
-
Mayer, E.L.1
Baurain, J.F.2
Sparano, J.3
Strauss, L.4
Campone, M.5
Fumoleau, P.6
Rugo, H.7
Awada, A.8
Sy, O.9
Llombart-Cussac, A.10
-
39
-
-
84893758436
-
Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer
-
Elsberger B. Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer. Critical reviews in oncology/hematology. 2014; 89:343-351.
-
(2014)
Critical reviews in oncology/hematology.
, vol.89
, pp. 343-351
-
-
Elsberger, B.1
-
40
-
-
77949848665
-
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
-
Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nature chemical biology. 2010; 6:291-299.
-
(2010)
Nature chemical biology.
, vol.6
, pp. 291-299
-
-
Li, J.1
Rix, U.2
Fang, B.3
Bai, Y.4
Edwards, A.5
Colinge, J.6
Bennett, K.L.7
Gao, J.8
Song, L.9
Eschrich, S.10
Superti-Furga, G.11
Koomen, J.12
Haura, E.B.13
-
41
-
-
38049018155
-
A quantitative analysis of kinase inhibitor selectivity
-
Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, et al. A quantitative analysis of kinase inhibitor selectivity. Nature biotechnology. 2008; 26:127-132.
-
(2008)
Nature biotechnology.
, vol.26
, pp. 127-132
-
-
Karaman, M.W.1
Herrgard, S.2
Treiber, D.K.3
Gallant, P.4
Atteridge, C.E.5
Campbell, B.T.6
Chan, K.W.7
Ciceri, P.8
Davis, M.I.9
Edeen, P.T.10
Faraoni, R.11
Floyd, M.12
Hunt, J.P.13
Lockhart, D.J.14
Milanov, Z.V.15
Morrison, M.J.16
-
42
-
-
36549040859
-
The selectivity of protein kinase inhibitors: a further update
-
Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. The Biochemical journal. 2007; 408:297-315.
-
(2007)
The Biochemical journal.
, vol.408
, pp. 297-315
-
-
Bain, J.1
Plater, L.2
Elliott, M.3
Shpiro, N.4
Hastie, C.J.5
McLauchlan, H.6
Klevernic, I.7
Arthur, J.S.8
Alessi, D.R.9
Cohen, P.10
-
43
-
-
80053594491
-
Src-family tyrosine kinases as therapeutic targets in advanced cancer
-
Gelman IH. Src-family tyrosine kinases as therapeutic targets in advanced cancer. Front Biosci (Elite Ed). 2011; 3:801-807.
-
(2011)
Front Biosci (Elite Ed).
, vol.3
, pp. 801-807
-
-
Gelman, I.H.1
-
44
-
-
84870020040
-
MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling
-
Huang S, Holzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, Neefjes J, Salazar R, Ten Dijke P, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell. 2012; 151:937-950.
-
(2012)
Cell.
, vol.151
, pp. 937-950
-
-
Huang, S.1
Holzel, M.2
Knijnenburg, T.3
Schlicker, A.4
Roepman, P.5
McDermott, U.6
Garnett, M.7
Grernrum, W.8
Sun, C.9
Prahallad, A.10
Groenendijk, F.H.11
Mittempergher, L.12
Nijkamp, W.13
Neefjes, J.14
Salazar, R.15
Ten Dijke, P.16
-
45
-
-
78650387482
-
Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis
-
Deblois G, Chahrour G, Perry MC, Sylvain-Drolet G, Muller WJ, Giguere V. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. Cancer Res. 2010; 70:10277-10287.
-
(2010)
Cancer Res.
, vol.70
, pp. 10277-10287
-
-
Deblois, G.1
Chahrour, G.2
Perry, M.C.3
Sylvain-Drolet, G.4
Muller, W.J.5
Giguere, V.6
|